Cellectar Biosciences, Inc. (CLRB) Press Releases https://www.cellectar.com/investors/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_82fb76d941e714ade0a9b4bd7ead767d/cellectar/files/theme/images/logo-sm.png Cellectar Biosciences, Inc. Logo /investors Equisolve Investor Relations Suite <![CDATA[Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia]]> https://www.cellectar.com/investors/news-events/press-releases/detail/390/cellectar-biosciences-reports-positive-12-month-follow-up-data-from-phase-2b-clover-wam-study-demonstrating-durable-responses-and-efficacy-of-iopofosine-i-131-in-rr-waldenstrm-macroglobulinemia Tue, 05 May 26 07:10:00 -0400 https://www.cellectar.com/investors/news-events/press-releases/detail/390/cellectar-biosciences-reports-positive-12-month-follow-up-data-from-phase-2b-clover-wam-study-demonstrating-durable-responses-and-efficacy-of-iopofosine-i-131-in-rr-waldenstrm-macroglobulinemia <![CDATA[Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million]]> https://www.cellectar.com/investors/news-events/press-releases/detail/389/cellectar-biosciences-announces-oversubscribed-financing-up-to-140-million Tue, 05 May 26 07:00:00 -0400 https://www.cellectar.com/investors/news-events/press-releases/detail/389/cellectar-biosciences-announces-oversubscribed-financing-up-to-140-million <![CDATA[Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026]]> https://www.cellectar.com/investors/news-events/press-releases/detail/388/cellectar-biosciences-announces-subset-of-clover-wam-clinical-trial-data-accepted-for-presentation-at-the-american-society-of-clinical-oncology-conference-2026 Tue, 21 Apr 26 10:00:00 -0400 https://www.cellectar.com/investors/news-events/press-releases/detail/388/cellectar-biosciences-announces-subset-of-clover-wam-clinical-trial-data-accepted-for-presentation-at-the-american-society-of-clinical-oncology-conference-2026 <![CDATA[Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)]]> https://www.cellectar.com/investors/news-events/press-releases/detail/387/cellectar-enrolls-first-patient-in-clr-125-auger-emitting-radioconjugate-phase-1b-clinical-trial-targeting-refractory-triple-negative-breast-cancer-tnbc Tue, 14 Apr 26 08:35:00 -0400 https://www.cellectar.com/investors/news-events/press-releases/detail/387/cellectar-enrolls-first-patient-in-clr-125-auger-emitting-radioconjugate-phase-1b-clinical-trial-targeting-refractory-triple-negative-breast-cancer-tnbc